1 |
Savarese T, Abate A, Basnet RM, Lorini L, Gurizzan C, Tomasoni M, Lombardi D, Tomasini D, Zizioli D, Memo M, Berruti A, Bonini SA, Sigala S, Bossi P. Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study. Sci Rep 2022;12:9951. [PMID: 35705678 DOI: 10.1038/s41598-022-14197-8] [Reference Citation Analysis]
|
2 |
Dozic B, Anicic B, Sinobad V, Mikovic N, Milanovic S, Dozic I. Expression of apoptotic protease activating factor-1 in adenoid cystic carcinoma of the salivary glands and its clinicopathological relevance. VSP 2022;79:427-32. [DOI: 10.2298/vsp201026130d] [Reference Citation Analysis]
|
3 |
Howard D, James D, Murphy K, Garcia-Parra J, Pan-Castillo B, Rex S, Moul A, Jones E, Bilbao-Asensio M, Michue-Seijas S, Lutchman-Singh K, Margarit L, Francis LW, Rees P, Gonzalez D, Conlan RS. Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer. Cancers (Basel) 2021;13:1135. [PMID: 33800911 DOI: 10.3390/cancers13051135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
4 |
Lorini L, Ardighieri L, Bozzola A, Romani C, Bignotti E, Buglione M, Guerini A, Lombardi D, Deganello A, Tomasoni M, Bonini SA, Sigala S, Farina D, Ravanelli M, Bossi P. Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. Oral Oncol 2021;115:105213. [PMID: 33578204 DOI: 10.1016/j.oraloncology.2021.105213] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
|